Thalassaemia trials in Germany
5 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Berlin, Freiburg im Breisgau
- Age
- 2 years and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - Phase 3Enrolling by invitationA Long-term Follow-up Study in Participants Who Received CTX001
- Where
- Duesseldorf, Regensburg, Tuebingen
- Age
- 2 years to 64 years
- People
- 160 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00 - Phase 2Taking peopleStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Where
- Essen, Ulm
- Age
- 6 years to 17 years
- People
- 99 worldwide
- Run by
- Celgene
See details and how to joinNCT04143724 · EU 2022-502499-22-00 - Phase 3Taking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, München
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 3Taking peopleEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- Where
- Duesseldorf
- Age
- 12 years to 35 years
- People
- 26 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT05477563 · EU 2024-514641-12-00